Insulin-like Growth Factors and Subsequent Risk of Mortality in the United States

Abstract

Although numerous studies have explored the relation of insulin-like growth factor (IGF)-I and IGF-binding protein (BP) 3 with cancer and cardiovascular disease, only two previous studies are known to have looked at the association of IGF-I and IGF-BP3 with risk of mortality. The objective of this US study was to examine the risk of all-cause, heart disease, and cancer mortality associated with IGF-I and IGF-BP3 levels using data from the Third National Health and Nutrition Examination Survey (NHANES III) and NHANES III Mortality Study (n = 6,061) (1988-2000). The authors constructed proportional hazards models with age as the time scale to determine the association of baseline IGF-I and IGF-BP3 levels with subsequent mortality. After adjustment for baseline measures, there was no increased risk of all-cause, heart disease, or cancer mortality for the lower quartiles of IGF-I compared with the highest quartile. The adjusted relative hazard of all-cause mortality for the lowest quartile of IGF-BP3 compared with the highest quartile was 1.57 (95% confidence interval: 0.98, 2.52), and the trend for risk was significant (p = 0.0364), but there was no increased risk of heart disease or cancer mortality. Results suggest that the association of IGF-I and IGF-BP3 with mortality may differ from associations with incidence of disease.

Relationship Between IGF-1 and Cortisol/ DHEA-S Ratio in Adult Men With Diabetic Metabolic Syndrome Versus Non-Diabetic Metabolic Syndrome

“…We also found signifi cant correlations between IGF-1 and WC, BP, FBG, HOMA, cortisol and Several epidemiological studies have linked low circulating total IGF-1 to an increased risk of the metabolic syndrome and its individual components [19][20][21]. In addition, patients with type 2 diabetes often exhibit reduced circulating total IGF-1 levels [14].…”

Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors

“…In the study by Bunderen et al (4) mentioned above, an increased risk for allcause mortality was found for elderly subjects with the lowest IGF1 levels in the 1st quintile compared with the 3rd quintile. Other studies have failed to show an association between IGF1 levels and all-cause mortality (9,(30)(31)(32). These conflicting results could be explained by differences in population age (O17 years in Saydah et al (32), 51-89 years in Laughlin et al (9) and O65 in Kaplan et al (28), race, and unrecognized differences in lifestyle factors that modulate IGF levels.…”

“…Other studies have failed to show an association between IGF1 levels and all-cause mortality (9,(30)(31)(32). These conflicting results could be explained by differences in population age (O17 years in Saydah et al (32), 51-89 years in Laughlin et al (9) and O65 in Kaplan et al (28), race, and unrecognized differences in lifestyle factors that modulate IGF levels. The impact of ACE inhibitors on CV and all-cause mortality was not taken into account in any of these studies.…”

Associations of IGF1 and IGFBPs 1 and 3 with all-cause and cardiovascular mortality in older men: the Health In Men Study

“…Lower IGF1 has been associated with increased IHD mortality, and with CVD or all-cause mortality (13)(14)(15). By contrast, several studies have found no association of IGF1 levels with mortality (16)(17)(18), or reported that higher IGF1 levels predicted all-cause mortality (19). One study reported a U-shaped association of IGF1 with CVD mortality (20).…”